Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04223843 · ClinicalTrials.gov registry record · Phase 4
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 213
- Enrollment target
NCT04223843 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 213 participants.
The verdict
NCT04223843, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 213 participants
- Enrollment target
Study Summary
To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat® on lung function in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with optimal and sub-optimal Peak Inspiratory Flow Rate (PIFR). Disease severity (moderate to severe) is based on the Global Initiative for Chronic Lung Disease (GOLD) guidelines (GOLD 2 - 3)
Interventions
- DRUG Placebo
- DRUG Tiotropium + olodaterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2020-01-08 |
| Est. Completion | 2020-09-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04223843
The ClinicalTrials.gov registry entry for NCT04223843 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04223843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04223843 about?
NCT04223843 is a clinical study titled "A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale". To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat® on lung function in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with optimal and sub-optimal Peak Inspiratory Flow Rate (PIFR). Disease severity (moderate to severe) is based on the Global ...
What is the current status of trial NCT04223843?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 213 participants. The study started on 2020-01-08. Estimated completion is 2020-09-29.
What interventions are being tested in trial NCT04223843?
The interventions under investigation include: Placebo (DRUG), Tiotropium + olodaterol (DRUG).
Who is sponsoring clinical trial NCT04223843?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.